StocksMedium•10 November 2026•
1 min read
J&J Reports Positive Phase 3 Results for CAPLYTA in Bipolar Mania Treatment
Key Facts
1Johnson & Johnson announced that the Phase 3 study of CAPLYTA met its primary and key secondary endpoints for treating bipolar mania episodes.
Johnson & Johnson announced that the Phase 3 study of CAPLYTA met its primary and key secondary endpoints for treating bipolar mania episodes. The company stated via PR Newswire that results from the second pivotal trial showed significant improvement in manic symptoms and overall illness severity, with noticeable improvements observed as early as Day 3 of treatment.
The positive data from the study will support a planned submission to the U.S. FDA for CAPLYTA to treat manic episodes in adults with bipolar I disorder. Regarding market performance, JNJ closed at $282.11 on November 9, 2026, with the stock trading between a low of $276.2 and a high of $282.73 during that session.